Radius Health, Inc. (NASDAQ:RDUS) major shareholder Growth N. V. Biotech acquired 60,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 16th. The stock was acquired at an average price of $35.98 per share, with a total value of $2,158,800.00. Following the completion of the acquisition, the insider now directly owns 5,248,799 shares of the company’s stock, valued at approximately $188,851,788.02. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Radius Health, Inc. (NASDAQ:RDUS) traded up 0.28% during midday trading on Friday, reaching $35.52. 539,938 shares of the company’s stock were exchanged. Radius Health, Inc. has a 52 week low of $31.58 and a 52 week high of $59.22. The company’s market cap is $1.55 billion. The firm has a 50-day moving average price of $41.97 and a 200 day moving average price of $40.13.
Radius Health (NASDAQ:RDUS) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.35) by $0.23. The business had revenue of $0.98 million for the quarter, compared to analysts’ expectations of $1.96 million. During the same period in the prior year, the company earned ($1.01) earnings per share. Analysts anticipate that Radius Health, Inc. will post ($5.51) EPS for the current year.
TRADEMARK VIOLATION NOTICE: This news story was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://stocknewstimes.com/2017/08/19/radius-health-inc-rdus-major-shareholder-growth-n-v-biotech-purchases-60000-shares-of-stock.html.
A number of equities research analysts have issued reports on RDUS shares. Canaccord Genuity restated a “buy” rating on shares of Radius Health in a report on Friday, April 28th. Cantor Fitzgerald restated a “buy” rating and set a $65.00 price target on shares of Radius Health in a report on Friday, April 28th. HC Wainwright restated a “buy” rating and set a $63.00 price target on shares of Radius Health in a report on Monday, May 15th. Finally, BidaskClub upgraded shares of Radius Health from a “hold” rating to a “buy” rating in a report on Tuesday, June 27th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $53.60.
A number of hedge funds have recently bought and sold shares of RDUS. Ameritas Investment Partners Inc. increased its stake in Radius Health by 19.9% in the second quarter. Ameritas Investment Partners Inc. now owns 3,266 shares of the biopharmaceutical company’s stock worth $148,000 after buying an additional 541 shares in the last quarter. California State Teachers Retirement System increased its stake in Radius Health by 6.1% in the second quarter. California State Teachers Retirement System now owns 65,950 shares of the biopharmaceutical company’s stock worth $2,983,000 after buying an additional 3,780 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in Radius Health by 17.3% in the second quarter. The Manufacturers Life Insurance Company now owns 27,677 shares of the biopharmaceutical company’s stock worth $1,251,000 after buying an additional 4,083 shares in the last quarter. RA Capital Management LLC acquired a new stake in Radius Health during the second quarter worth about $22,486,000. Finally, State Street Corp increased its stake in Radius Health by 12.9% in the second quarter. State Street Corp now owns 1,867,531 shares of the biopharmaceutical company’s stock worth $84,473,000 after buying an additional 213,399 shares in the last quarter. 97.66% of the stock is owned by hedge funds and other institutional investors.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
